Thalidomide treatment in a myelofibrosis patient with leukemia transformation

Wei Han Huang, Ming Shing Li, Sung Chao Chu, Tso Fu Wang, Ruey Ho Kao, Yi Feng Wu

研究成果: 雜誌貢獻文章

2 引文 (Scopus)

摘要

Primary myelofibrosis is a clonal disease of chronic myeloproliferative neoplasm, and is a progressive clinical course with short median survival of less than 5 years after diagnosis. Leukemic transformation occurs in 8-23 % of myelofibrosis patients, and survival is about 3 months after transformation to leukemia. Thalidomide, an oral immunomodulatory drug, has been used effectively in the treatment of primary myelofibrosis, in which some patients could become transfusion independent, and showed improvement in thrombocytopenia and reduction in spleen size. Here, we report a patient with primary myelofibrosis with leukemic transformation who survived for more than 6 years with thalidomide monotherapy. Thalidomide may be beneficial for some myelofibrosis patients with leukemic transformation for whom intensive chemotherapy is not indicated.
原文英語
頁(從 - 到)188-192
頁數5
期刊International Journal of Hematology
99
發行號2
DOIs
出版狀態已發佈 - 二月 1 2014
對外發佈Yes

指紋

Primary Myelofibrosis
Thalidomide
Leukemia
Therapeutics
Survival
Thrombocytopenia
Chronic Disease
Spleen
Drug Therapy
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Hematology

引用此文

Thalidomide treatment in a myelofibrosis patient with leukemia transformation. / Huang, Wei Han; Li, Ming Shing; Chu, Sung Chao; Wang, Tso Fu; Kao, Ruey Ho; Wu, Yi Feng.

於: International Journal of Hematology, 卷 99, 編號 2, 01.02.2014, p. 188-192.

研究成果: 雜誌貢獻文章

Huang, Wei Han ; Li, Ming Shing ; Chu, Sung Chao ; Wang, Tso Fu ; Kao, Ruey Ho ; Wu, Yi Feng. / Thalidomide treatment in a myelofibrosis patient with leukemia transformation. 於: International Journal of Hematology. 2014 ; 卷 99, 編號 2. 頁 188-192.
@article{3a780989f3be4822b18247c7cc86ed54,
title = "Thalidomide treatment in a myelofibrosis patient with leukemia transformation",
abstract = "Primary myelofibrosis is a clonal disease of chronic myeloproliferative neoplasm, and is a progressive clinical course with short median survival of less than 5 years after diagnosis. Leukemic transformation occurs in 8-23 {\%} of myelofibrosis patients, and survival is about 3 months after transformation to leukemia. Thalidomide, an oral immunomodulatory drug, has been used effectively in the treatment of primary myelofibrosis, in which some patients could become transfusion independent, and showed improvement in thrombocytopenia and reduction in spleen size. Here, we report a patient with primary myelofibrosis with leukemic transformation who survived for more than 6 years with thalidomide monotherapy. Thalidomide may be beneficial for some myelofibrosis patients with leukemic transformation for whom intensive chemotherapy is not indicated.",
keywords = "Acute leukemia, JAK2, Myelofibrosis, Thalidomide",
author = "Huang, {Wei Han} and Li, {Ming Shing} and Chu, {Sung Chao} and Wang, {Tso Fu} and Kao, {Ruey Ho} and Wu, {Yi Feng}",
year = "2014",
month = "2",
day = "1",
doi = "10.1007/s12185-013-1478-6",
language = "English",
volume = "99",
pages = "188--192",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Thalidomide treatment in a myelofibrosis patient with leukemia transformation

AU - Huang, Wei Han

AU - Li, Ming Shing

AU - Chu, Sung Chao

AU - Wang, Tso Fu

AU - Kao, Ruey Ho

AU - Wu, Yi Feng

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Primary myelofibrosis is a clonal disease of chronic myeloproliferative neoplasm, and is a progressive clinical course with short median survival of less than 5 years after diagnosis. Leukemic transformation occurs in 8-23 % of myelofibrosis patients, and survival is about 3 months after transformation to leukemia. Thalidomide, an oral immunomodulatory drug, has been used effectively in the treatment of primary myelofibrosis, in which some patients could become transfusion independent, and showed improvement in thrombocytopenia and reduction in spleen size. Here, we report a patient with primary myelofibrosis with leukemic transformation who survived for more than 6 years with thalidomide monotherapy. Thalidomide may be beneficial for some myelofibrosis patients with leukemic transformation for whom intensive chemotherapy is not indicated.

AB - Primary myelofibrosis is a clonal disease of chronic myeloproliferative neoplasm, and is a progressive clinical course with short median survival of less than 5 years after diagnosis. Leukemic transformation occurs in 8-23 % of myelofibrosis patients, and survival is about 3 months after transformation to leukemia. Thalidomide, an oral immunomodulatory drug, has been used effectively in the treatment of primary myelofibrosis, in which some patients could become transfusion independent, and showed improvement in thrombocytopenia and reduction in spleen size. Here, we report a patient with primary myelofibrosis with leukemic transformation who survived for more than 6 years with thalidomide monotherapy. Thalidomide may be beneficial for some myelofibrosis patients with leukemic transformation for whom intensive chemotherapy is not indicated.

KW - Acute leukemia

KW - JAK2

KW - Myelofibrosis

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84894415424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894415424&partnerID=8YFLogxK

U2 - 10.1007/s12185-013-1478-6

DO - 10.1007/s12185-013-1478-6

M3 - Article

VL - 99

SP - 188

EP - 192

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -